Headquartered at Vadodara in Gujarat, Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company that manufactures and markets generic products all over the world, reported growth in net profit by 9.1 percent at ₹48.27 crore for the quarter ended December 31, 2012 against ₹44.23 crore in corresponding quarter last fiscal. The company posted 12.2 percent growth in profit before tax at ₹60.09 crore for the quarter against ₹53.54 crore posted in corresponding quarter last fiscal. Alembic posted total revenue of ₹372.05 crore for the quarter ended December 31, 2012, compared to ₹382.82 crore in the corresponding quarter last year.

The domestic formulations business posted sales of ₹227.64 crore against ₹198.78 crore with a 15 percent growth over the corresponding quarter of the previous year against the backdrop of slowing growth rate of IPM. Alembic maintained market share of 1.76 percent Azithral was ranked 25th and Alembic has three other brands in the list of top 300 brands of industry i.e. 'Althrocin', 'Roxid', and 'Wikoryl'. The chronic and acute segments grew by 23 percent and 4 percent respectively in current year.

The company that has launched a dermatology division in current fiscal year, has state of the art brands, which are marketed through a team of over 3600. The international Generic Formulation sales is ₹61.05 crore against ₹58.45 crore over the corresponding quarter last year. During the quarter six ANDA application was filed taking cumulative ANDA and NDA filings of the company to 55. Cumulative ANDA approvals now stands at 21.